[
  {
    "ts": null,
    "headline": "Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'",
    "summary": "Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.",
    "url": "https://finnhub.io/api/news?id=e71bbbd2420df44d840a777ac582482b0cea64f77fabe75a60f9d2d708498919",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757020459,
      "headline": "Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'",
      "id": 136641766,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.",
      "url": "https://finnhub.io/api/news?id=e71bbbd2420df44d840a777ac582482b0cea64f77fabe75a60f9d2d708498919"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Announces Updated Presentation Time for Upcoming Investor Conference",
    "summary": "TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025. The presentation will be webcast live and may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcast will be archived on the Company's web",
    "url": "https://finnhub.io/api/news?id=1bfc791ca8cedd3477c3c5b64319dc90485c0aaa88c595fddf82153c647fc325",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757019900,
      "headline": "Regeneron Announces Updated Presentation Time for Upcoming Investor Conference",
      "id": 136642448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025. The presentation will be webcast live and may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcast will be archived on the Company's web",
      "url": "https://finnhub.io/api/news?id=1bfc791ca8cedd3477c3c5b64319dc90485c0aaa88c595fddf82153c647fc325"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
    "url": "https://finnhub.io/api/news?id=99672322321f5ad7113e1732e7950765b7f5315f214960c660855ee44ee12fc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757007155,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
      "id": 136639750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
      "url": "https://finnhub.io/api/news?id=99672322321f5ad7113e1732e7950765b7f5315f214960c660855ee44ee12fc3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript",
    "summary": "Get the latest insights on Regeneron's pipeline, EYLEA HD growth",
    "url": "https://finnhub.io/api/news?id=ac5bb2781396971b491561c25183b5379df2e10fb119f056926928c59911c9a2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757001816,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript",
      "id": 136639255,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Get the latest insights on Regeneron's pipeline, EYLEA HD growth",
      "url": "https://finnhub.io/api/news?id=ac5bb2781396971b491561c25183b5379df2e10fb119f056926928c59911c9a2"
    }
  },
  {
    "ts": null,
    "headline": "SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study",
    "summary": "Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.",
    "url": "https://finnhub.io/api/news?id=3d35b846d1b0ab8fce06426da24a7f95b65960ec7a2e219eb84cc2e2fe6107cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757000880,
      "headline": "SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study",
      "id": 136642450,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.",
      "url": "https://finnhub.io/api/news?id=3d35b846d1b0ab8fce06426da24a7f95b65960ec7a2e219eb84cc2e2fe6107cf"
    }
  },
  {
    "ts": null,
    "headline": "Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best",
    "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers.",
    "url": "https://finnhub.io/api/news?id=ab468159ca5d0d2965c56bf593013823948e4e5e08aa36cb5fee2a49cd234a02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756960346,
      "headline": "Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best",
      "id": 136642451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers.",
      "url": "https://finnhub.io/api/news?id=ab468159ca5d0d2965c56bf593013823948e4e5e08aa36cb5fee2a49cd234a02"
    }
  }
]